Endocrine Abstracts

Introduction: Immunotherapy has revolutionized the treatment of cancer. Nivolumab, an anti-programmed cell death 1(PD-1) antibody, is used to treat several malignancies refractory to standard chemotherapy. While highly effective at prolonging patient survival, these agents can induce a wide range of endocrine immune-related adverse events (irAEs), including hypophysitis, thyroid dysfunction, and, uncommonly, type 1 diabetes (T1DM). Here we describe a rare case of PD-1 inhibito...